NEW WEBSITE We would like to invite you to a sneak peak of our new website before it goes live. Visit the new site

Drug Discovery and Development Platform (DDD)

National platform

The SciLifeLab Drug Discovery and Development platform offers integrated drug discovery efforts to the Swedish academic research community. We offer industry standard infrastructure, expertise, and strategic support to help progress projects towards a preclinical proof-of-concept. The drug leads can be either a small molecule drug or a human antibody therapeutic. Services are offered in the following areas:

  • Up to 80 hour free support to prepare your project as a drug discovery project, including an initial drug target product profile, and a lead generation/antibody selection strategy with progression plans
  • In collaboration with Chemical Biology Consortium Sweden, logistic solutions and data management for sharing of large number of compounds (SciLifeLab compound collection)/antibodies. For more details contact Åsa Slevin,
  • In collaboration with Chemical and Pharmaceutical Toxicology at RISE (Södertälje), projects are evaluated for target safety concerns and approved projects are offered chemical toxicity support (in silico profiling of small molecules), immunotoxicity support (antibodies) and safety support in the design of in vivo studies. For more details contact Björn Glinghammar,
  • Protein production for assay development
  • Identification of binders from our IP free phage display library of human antibodies
  • Biochemical and cellular screening, both at single concentration in large compound libraries and to generate dose response data for iterative chemistry
  • Medicinal synthetic and computational chemistry
  • Analysis of drug metabolism and pharmacokinetics data for compounds and antibodies
  • Advanced analysis of in vitro pharmacology and systems pharmacology of compounds and antibodies
  • Biophysical identification of binding partners (small molecules or proteins), screening of chemical libraries and characterisation of interactions between hits/leads and their targets, using a range of time-resolved and structure-based biophysical methods

Importantly, the researcher/customer retains all rights and ownership during this process.

We encourage all academic researchers with an interest in turning their discoveries into cures for patients to contact us. For more information for how to start a project, please contact us via


For updates from the platform, find us on LinkedIn. Announcements of symposia and sources are also published in the SciLifeLab newsletter.

Current portfolio:

Platform Steering Group

Håkan Billig, Chair (University of Gothenburg)
Charlotte Edenius (Allmora Life Science)
Mef Nilbert (Lund University)
Anna Sandström (AstraZeneca, ex-Vinnova)
Maria Jenmalm (Linköping University)
Tomas Lundqvist (RISE)
Lars Lannfelt (UU)

Platform directors
Per Arvidsson, Platform Director (Karolinska Institutet)
Kristian Sandberg, Platform Co-Director (Uppsala Universitet)

Our achievements

Five years from empty labs and without personnel to:

  • 2 programs in Clinical Phase 1
  • 3 internationally partnered projects
  • 3 new Swedish Biotechs
  • >250 academic ideas evaluated
  • 18 DDD programs/year running at full capacity
  • Support to 3 European Union IMI projects
  • 40 additional projects/year incl. industry supported
  • 5 universities with DDD laboratories & staffed
  • 40+ professional staff
  • 3 industry partnerships since legal operating ability in May 2019

Recent successes: